# Validation of Therapeutic Efficacy Targeting the Splicing Variants in Cystic Fibrosis and CFTR Pathologies

> **NCT05100823** · NA · TERMINATED · sponsor: **University Hospital, Montpellier** · enrollment: 16 (actual)

## Conditions studied

- Cystic Fibrosis
- CFTR Gene Mutation

## Interventions

- **PROCEDURE:** Nasal cells sampling
- **PROCEDURE:** Rectal biopsy sampling

## Key facts

- **NCT ID:** NCT05100823
- **Lead sponsor:** University Hospital, Montpellier
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-30
- **Primary completion:** 2025-02-17
- **Final completion:** 2025-02-17
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Enrolment period completed and sufficient number of enrolments to achieve study objectives
- **Last updated:** 2025-09-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05100823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05100823, "Validation of Therapeutic Efficacy Targeting the Splicing Variants in Cystic Fibrosis and CFTR Pathologies". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05100823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*